At the cellular level, expansion of haemopoiesis in chronic myeloid leukaemia (CML) must involve some imbalance in cell production along the myeloid maturation pathway. The relevant kinetic parameters are cell loss by apoptosis and differentiation and cell gain by proliferation (self-renewal). In spite of the predominance of the BCR-ABL-positive leukaemic cells, some BCR-ABL-negative, presumably normal, progenitor cells remain for long periods in chronic phase CML. Thus, understanding the kinetics of CML and normal progenitor cells may lead to therapeutic strategies capable of reducing malignant cell growth and reactivating normal haemopoiesis.
Introduction
Chronic myeloid leukaemia (CML) is a malignant myeloproliferative disease that is manifest by well differentiated myeloid hyperplasia during its chronic phase. This is presumed to be the result of changes induced by the expression of the p210 protein tyrosine kinase product of the BCR-ABL fusion gene that is formed by the Philadelphia (Ph) chromosomal translocation between chromosomes 9 and 22. However, the link between the molecular and cellular phenotypes remains poorly understood, and one challenge is to explain how the acquisition of the Ph chromosome by a single haemopoietic stem cell can result in the overproduction of cells of the granulocytic series. 1 Another challenge is to document the fate of the residual normal haemopoietic stem cell population since this is crucial for the success of any treatment strategies apart from allogeneic bone marrow transplantation. The coexistence of primitive Ph-negative cells with primitive Ph-positive cells 2, 3 and the virtual absence of mature Ph-negative cells from the blood and bone marrow of patients with chronic phase CML suggests that the Ph-positive clone suppresses mature cell production by normal Ph-negative pluripotent stem cells. Presumably, however, suppression of normal haemopoiesis requires some expansion of the Ph-positive clone, and is not a feature of CML at its inception. Indeed, it has been estimated that it takes an average of 8 years for the Ph-positive clone to replace normal haemopoeisis. 4 The importance of understanding the cell biology of CML cannot be overstated because it will influence new approaches to therapy. The third challenge, then, is to understand the biology of normal and malignant stem cells in CML sufficiently well to be able to shift the balance of any proliferative advantage in favour of the normal stem cells and effect repopulation of the haemopoietic system with normal haemopoietic cells.
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Malignant cell expansion
As indicated by Figure 1 , there is a limited number of ways in which leukaemic cell expansion in CML might be achieved. The size of any cell compartment is determined by the balance between cell gain and cell loss. Gain consists of input from an antecedent cell population plus the products of cell division (mitosis) within the compartment itself. Loss consists of exit by cell differentiation (which provides the input into the next compartment in the sequence) plus cell death (apoptosis). By definition, there is no input into the stem cell compartment, and all of the gain is provided by mitosis (selfrenewal). In terminally differentiated cell populations all of the cell loss will be by apoptosis. Clearly, imbalance in any of these parameters will lead to an overall increase or decrease in the haemopoietic cell mass.
Whilst it may be convenient to display cell populations in compartments it must be remembered that the proliferation and maturation/differentiation of cells are the result of the activation of separate, although possibly overlapping sets of genes. These are probably the molecular correlates of the kinetic events we seek to understand.
Apoptosis
One explanation for the increase in myelopoiesis in CML would be provided if progenitor cell susceptibility to apoptosis was reduced. This is supported by studies in which otherwise growth factor-dependent cell lines become factor-independent when molecularly induced to express p210 BCR-ABL 5, 6 suggesting that they are resistant to the apoptosis normally suffered by the cell lines in the absence of growth factor. Paradoxically, however, the same cell lines become more sensitive to apoptosis induced by ionising radiation when they express p210. 7 We and others 8, 9 performed similar experiments using primary haemopoietic progenitor cells from normal individuals and chronic phase CML patients in place of cell lines, with conflicting results. In particular, Bedi and colleagues 9 reported that CML progenitor cells (CFU-GM) were less sensitive to apoptosis induced by growth factor deprivation or irradiation in vitro whereas Amos et al 8 could find no difference. These
Figure 1
Diagrammatic representation of kinetic relationships between successive compartments of haemopoietic cells. discrepant results might be accounted for if any differences in susceptibility to apoptosis in CML were a result of secondary changes in CML progenitor cells rather than a primary cause of myeloid expansion.
Both of the above studies 8, 9 investigated small numbers (ෂ5) of CML patient and control samples. We reasoned that investigation of larger numbers of individuals might be more informative. Here, we have measured the radiation sensitivity of clonogenic cells from the bone marrow of 16 normal individuals and the peripheral blood of 27 chronic phase CML patients. The data in Figure 2(a) , show the proportions of CFU-GM surviving exposure to 300 cGy in vitro from each individual. The median survival was lower for CFU-GM from CML patients than for normal CFU-GM (8 vs 14.4%) and the range of survival values was wider for CML CFU-GM than for normal CFU-GM (0.01-79 vs 0.7-52%). These differences were statistically significant (P = 0.02; Mann-Whitney U test). Plotting the data as a distribution (Figure 2(b) ) revealed a significant right skew for the CML results (coefficient of skewness = 4.11) but the normal cell data were normally distributed. This result suggests that CML progenitor cells are more likely to be more sensitive to irradiation, compared with normal cells, than to be less sensitive than normal. It argues against apoptosis being a primary mechanism in the pathogenesis of CML. Instead it suggests that secondary changes in CML may produce increased or decreased radiosensitivity of myeloid progenitors.
That reduced susceptibility to apoptosis is not a primary abnormality in CML progenitor cells is supported by Albrecht et al 10 using gamma irradiation or growth factor deprivation for apoptosis induction. Other work has indicated that BCR-ABL does not prevent apoptotic cell death induced by human natural killer cells or lymphokine-activated killer cells. 11 Thiele et al 12 used the in situ end-labelling (ISEL) technique on bone marrow smears and trephine biopsies and found evidence of significantly higher rates of apoptosis in CML than in normal samples.
It remains possible that there are maturation stage-specific differences in susceptibility to apoptosis. Indeed, it has been known for many years that neutrophils in CML disappear from the blood less rapidly than normal neutrophils. [13] [14] [15] More recently, this aspect has been investigated by Gisslinger et al 16 who found that there was some delay in CML neutrophil cell death compared to normal, although this might, in part, reflect premature release from the bone marrow. [17] [18] [19] Although the increased lifespan of mature neutrophils in CML will contribute to expansion of the myeloid mass, Clarkson and colleagues 20 have estimated that it is not sufficient to account for the total expansion of CML myelopoiesis and propose that granulocyte production must be substantially increased as well.
Susceptibility to apoptosis by normal and CML cells has important implications for therapy. In this regard, Thiele et al 12 found that interferon, but not busulphan, enhanced the level of apoptosis in sequential trephine biopsies. In vitro experiments also suggest that interferon alpha exerts its therapeutic effect by inducing apoptosis. 21 Carlo-Stella et al 
Proliferating fraction
Normally, a large proportion of primitive haemopoietic progenitor cells is in the Go (quiescent) phase of the cell cycle. An increased proliferating cell fraction might be expected to achieve a new steady-state with increased cellularity and a high white cell count rather than resulting in the progressive increase in cell number that is seen in untreated chronic phase CML.
In contrast to primitive normal haemopoietic progenitor cells, some studies show that most leukaemic equivalents in CML appear to be actively cycling. This has been demonstrated by studies using the long-term bone marrow culture S67 system, 23 and an increased fraction of proliferating vs quiescent primitive cells has been proposed as a cause of the increase the myeloid mass in CML. However, Clarkson et al 20 have also considered the proliferating fraction of progenitor cells in CML and found it to be lower than normal.
Control of the proliferating fraction of haemopoietic progenitor cells could be provided by interaction with stromal cells of the haemopoietic microenvironment. It is relevant, therefore, that in 1987 we found that primitive CML progenitor cells were defective with respect to their ability to interact with bone marrow-derived stromal cells via cell adhesion molecules and their ligands. 24 Similar findings of an abnormal adhesive phenotype in CML have been made by Upadhyaya et al, 25 Verfaillie et al 26 and Ghaffari et al. 27 Our studies have suggested that contact with stromal cells can reduce the probability of quiescent primitive progenitor cells entering active cell cycle. 28 Thus, primitive quiescent (in vivo) plastic-adherent pre-CFU-GM cells (P delta cells -Ref. 29) , cultured in the absence of stromal cells rapidly become activated in vitro and produce CFU-GM within 1 week. The P delta cells also have the ability to adhere to stromal cells 30 and, when stromal cells are added to the culture system, the production of CFU-GM at one week is markedly reduced (Ref 28 and Figure 3 ). Instead, CFU-GM production is delayed for up to 5 weeks 28 suggesting that the probability of cells becoming activated is reduced in the presence of stroma. When we performed the same experiment using P delta cells from patients with chronic phase CML we found that, in contrast to the response of normal cells, the presence of stromal cells increased the production of CFU-GM (Figure 3 ). This result indicates that the probability of CML P delta cells entering cell cycle is not reduced in the presence of stromal cells, and is consistent with an increased proliferating fraction of progenitor cells in CML.
Figure 3
Different effects of stromal cells on the production of CFU-GM by P delta cells. Suspensions of 10 7 mononuclear cells from normal bone marrow or CML blood were placed in 25 cm 2 tissue culture flasks, allowed to adhere for 2 h and non-adherent cells washed away. Disaggregated stromal cells, obtained by scraping confluent stromal cell cultures initiated with 10 7 mononuclear marrow cells, were added to half of the flasks. The flasks were incubated for 7 days, then non-adherent cells were harvested from the supernatant and assayed for CFU-GM. Stromal cells suppressed the production of CFU-GM by normal P delta cells but increased the production of CFU-GM by P delta cells in CML (see Refs 23 and 27).
Proliferation rate
An increase in stem cell proliferation rate, as a result of a reduction in cell cycle time, would not itself increase the size of the stem cell population if the other stem cell parameters remain unaltered (ie steady-state). It could increase the sizes of subsequent cell compartments if it resulted in them having increased gain over time without a commensurate increase in cell loss. In general, however, there is little evidence that malignant cells proliferate more rapidly than their normal counterparts. Indeed, cell kinetic studies in vivo indicate that CML cells proliferate more slowly than their normal counterparts. 17, 18 More recently, Thiele et al 12 used monoclonal antibody against proliferating cell nuclear antigen (PCNA) on bone marrow smears and trephine biopsies. They found that the PCNA labelling index of CML preparations was not different from normal controls.
Self-renewal
An increased probability of self-renewal by primitive cells, together with a commensurate decrease in the probability of differentiation would be anticipated to increase the size of the primitive progenitor cell population. As indicated in Figure 1 , steady-state conditions obtain when the probability of stem cell renewal is 0.5 and balanced by a probability of stem cell differentiation of 0.5. An increase in stem cell number requires an increase in self-renewal probability above 0.5 as shown by the model diagram in Figure 4 (a). In 1986, Dowding and colleagues 31 hypothesized that an increase in the probability of Ph-positive stem cell renewal above 0.5 leads to a progressive increase in the size of the Ph-positive stem cell pool. The corresponding probability of differentiation is less than 0.5, leading to a temporary deficit in the production of differentiating progeny. However, once the stem cell population expands sufficiently to compensate for this reduction in the probability of differentiation, the numbers of cells in successive compartments will increase in parallel with the stem cells (Figure 4(b) ).
The Dowding hypothesis would explain why steady-state normal haemopoiesis is overwhelmed by the CML cell mass. A different relationship can be seen when normal and CML cells are placed in conditions that stimulate cell proliferation. Thus, in long-term cultures CML cells apparently exhibit a proliferative defect compared with normal cells in the same circumstances. 32 In effect, this restates the concepts of Skipper and Perry 33 later applied by Eaves and Eaves 23 to the 'Tortoise vs Hare' hypothesis. According to Skipper and Perry, one of the reasons for successful anti-leukaemia therapy was that normal haemopoietic cells are able to regenerate faster after chemotherapy than malignant haemopoietic cells. This situation is unlikely to apply to unpurturbed chronic phase CML when the majority of normal stem cells presumably will be quiescent. As a result of their ability to regenerate faster than CML cells, normal cells might be better able to recover than CML cells following chemotherapy. This could lead to residual normal haemopoiesis reaching detectable levels at least temporarily ( Figure 5 ). It is quite obvious from the diagram that this effect will be visible only if there is a substantial level of residual normal haemopoiesis before therapy and/or there is an 'overshoot' in normal cell production after regeneration.
We investigated the size of the primitive progenitor cell population in CML using the 'P delta' assay for primitive pre- CFU-GM human haemopoietic cells. 29 The assay was performed at limiting dilution so that we could measure the frequency of the P delta cells and determine whether this population is expanded in CML. We found that the frequencies of the P delta cells in CML blood, CML marrow and normal marrow were similar, implying an increase in P delta population size in CML when increased cellularity is taken into account. This finding is consistent with increased self-renewal. We also could measure the ability of individual P delta cells to produce CFU-GM. We found a decrease in the number of CFU-GM produced per CML P delta cell, compared with normal marrow values which is consistent with a reduced probability of differentiation at this level of haemopoietic cell development. 34 
CFU-GM expansion (the discordant maturation hypothesis)
In contrast to the Dowding hypothesis which suggests that leukaemic stem cell proliferation alone can explain myeloid Illustration of events during the development and treatment of CML. Initially, CML cell numbers increase faster than normal cells but both are decreased in number by therapy. Then the normal cells regenerate faster than the CML cells and may 'overshoot' the pretreatment number. The likelihood that normal cell recovery is visible as Philadelphia-negative haemopoiesis must depend on the size of the residual normal cell population compared with the number of CML cells. expansion in CML, the Discordant Maturation hypothesis proposes that the more mature proliferating cells in chronic phase CML are responsible for the expansion of the Ph-positive cell population. 35 It is quite reasonable to believe that the Ph-positive stem cell population expands during its history, otherwise there would never be more than one or two of them. Clarkson and colleagues 20 also have concluded that the initial expansion in CML originates in the primitive progenitor cell compartment. However, other features of the Dowding model, in particular the parallel increases in stem cell and differentiated cell numbers, need to be examined more closely.
Stryckmans and colleagues 17 noted that the number of immature (proliferating) granulocytic cells in the blood of CML patients off treatment increases more rapidly (doubling time 50 days) than the total white cell count (doubling time 84 days) and that when the respective counts were plotted on semi-log graphs they did not produce parallel lines. Their observations indicate that the immature granulocytes increase 1.7 times faster than the white cell count. Eaves and Eaves 36 provided data on the relationship between circulating CFU-GM numbers and the white cell count which implied that the CFU-GM increase 100 times more rapidly than the white cell count. These two studies show that the relationships between successive cell populations are, in fact, not parallel. The relationships themselves provide evidence for amplification within the CFU-GM compartment and for ineffective granulopoiesis at the post-progenitor level.
To test for expansion in the CFU-GM compartment we have used the replating ability of CFU-GM colonies as an index of self-replication. These experiments confirmed that CFU-GM grown from CML cells produce more secondary CFU-GM when they are replated than do CFU-GM grown from normal cells. 37 This result indicates that there is preferential expansion of myelopoiesis at the CFU-GM level in CML. Thus, pre-CFU-GM (P delta cells) in CML appear to have a subnormal ability to produce CFU-GM (see above) but the CFU-GM themselves appear to have a greater expansion capacity in CML than in normal haemopoiesis.
The suggestions that a large component of myeloid expan-S69 sion in CML occurs within the CFU-GM compartment, and that there may be ineffective granulopoiesis at the later stages of granulocyte maturation, seems to be in complete agreement with the Discordant Maturation hypothesis of Clarkson and coworkers. 20 Their results demonstrate that in CML there is 10 times the normal number of day 3 CFU-GM, but only 2 times the normal number of day 14 CFU-GM. If the day 14 CFU-GM are considered to be the precursors of the day 3 CFU-GM, this observation indicates that expansion at this stage of cell development is 5 times normal and supports increased cell production in the CFU-GM compartment in CML. Also, Clarkson et al 20 found that the average number of cells per CFU-GM colony in CML is less than the average number of cells in normal CFU-GM colonies. This observation means that CML CFU-GM are less able to produce progeny than normal CFU-GM, either as a result of ineffective granulopoiesis or because the CML progenitors are at a more advanced stage of maturation than normal progenitors. Whichever explanation is correct, this is consistent with a disproportionate expansion of the CFU-GM compartment in CML.
Progression to blast crisis
The natural history of CML almost inevitably leads to transformation to acute leukaemia, or blast crisis. It is generally accepted that this transformation is associated with the acquisition of further genetic changes, but whether these are an essential component is not certain. A supplementary component to transformation is suggested by the data of Stryckmans et al. 17 As mentioned above, they demonstrated that the number of immature 'proliferating' granulocytic cells (PGs) in the bloodstream of patients with CML increases more rapidly than the white cell count. In other words, the percentage of blasts increases with time. Consequently, extrapolation of their data will predict the time at which the differential white cell count will consist of 50% immature cells. In the patient reported by Stryckmans et al this would have been predicted to occur ෂ60 weeks after the start of observation. This relationship could provide information that is relevant to prognosis and/or response to therapy.
It is improbable that the increasing proportions of immature cells are responsible for transformation to acute phase disease since the cells in blast crisis are more monomorphic and have an aggressively malignant phenotype. More likely is the widely accepted view that progression to blast crisis involves genetic instability and the resultant acquisition of secondary transforming genetic changes. Genetic instability could result either from an intrinsic mechanism or from the increased amount of cell proliferation in CML, ie more cells at risk. It seems clear that genetic instability and secondary changes must be associated with an increase in self-renewal probability in order for the abnormality to become established in the population and contribute to the evolution of the disease. This would explain why subclones arrested at the blastic stage, and with an even lower growth fraction than the chronic phase population are capable of rapidly replacing normal or chronic phase CML precursors. 20 
Normal cells in CML
There is great interest in the status of the residual Ph-negative stem cell population in the blood and marrow of patients with chronic phase CML. The first confirmation that Ph-negative progenitors exist in CML patients came from cytogenetic analysis of cells in CFU-GM-derived colonies. 38 More recently, haemopoietic progenitor cell subpopulations have been examined and techniques such as RT-PCR and FISH have been used.
As might be predicted from the preferential expansion of the CFU-GM compartment (see above), the proportions of Phnegative cells are not uniform throughout all stages of haemopoietic cell development. The Ph-negative cells appear to be more frequent in primitive haemopoietic cell populations than in the more mature compartments. 3 Some studies have implied that all of the primitive (stem) cells in CML patients are Ph-negative whilst the great majority of the CFU-GM are generally found to be positive. These results have led to some people expressing the extreme view that all stem cells in CML patients are Ph-negative/normal. However, this would require the leukaemic stem cell progeny, such as CFU-GM, to be entirely self-maintaining or to arise de novo to explain their presence in large numbers in CML.
Our own studies focussed on the primitive cell population characterised by expression of the CD34 antigen, but not of CD38 or HLA-DR, adherence to tissue culture plastic and the ability to generate CFU-GM in the P delta assay. We found that the frequency of Ph-negative cells was significantly higher in this cell population (P = 0.001) than amongst less primitive CD34-positive non-adherent cells, but that the majority (Ͼ80%) of the cells were Ph-positive. 2 The detection of BCR-ABL-negative primitive cells in CML patients in whom 100% of the mature cells are BCR-ABL-positive implies that normal cell proliferation is inhibited by the leukaemia clone. The mechanism for this suppression is not clear but might relate to negative feedback from the greatly increased neutophil count.
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Targets for therapy
The various abnormalities in CML progenitor cell populations compared with normal cells indicate targets that might be attacked with therapeutic benefit.
Stem cells
CML originates in a single Ph-positive stem cell and the leukaemic stem cell population presumably is the ultimate target for therapy. Since blast crisis in CML may be either lymphoid or myeloid, and therefore derived from pluripotent Ph+ pluripotent progenitors, eradication of CML stem cells may be essential for cure. Destruction of the leukaemic cell clone by myeloablative chemoradiotherapy and replacement of the normal stem cells by allogeneic bone marrow transplantation was, until the introduction of interferon-alpha, the only treatment offering the possibility of cure in CML.
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Progression
The apparently progressive nature of the chronic phase of CML led to the idea that blood cells harvested by leukapheresis at presentation could be cryopreserved and used later as an autograft following myeloablative therapy. 41 The rationale for this approach was that reinfusion of early chronic phase cells would reset the tempo of the disease. It is clear that some prolongation of chronic phase can be achieved by autograft-ing. Also, many patients experience a period of at least partial Ph-negative (presumably normal) haemopoiesis which is likely to result from the kinetic differences between normal and CML cells illustrated in Figure 5 .
The possibility remains that progression to blast crisis is related to an intrinsic genetic instability of CML cells resulting in the acquisition of secondary genetic abnormalities and transformation to acute leukaemia. Consequently, if the mechanisms of genetic instability were to be understood, reinstatement of genetic stability would be a theoretical approach to therapy in CML.
CFU-GM expansion
The preferential expansion of myelopoiesis in CML that occurs in CML offers a further target for therapy. Recently, we have found that interferon alpha, which has a definite therapeutic effect in CML, 42, 43 has a differential effect on CML CFU-GM expansion in vitro compared with normal cell expansion. 37 However, this strategy may not prevent progression to blast crisis which can derive from the pluripotent Ph-positive stem cell population (see above).
Stromal cell adhesion
We and others 44, 45 have suggested that the restoration of adhesive capacity of CML progenitor cells to stromal cells might restore negative regulation to the CML clone and be of therapeutic benefit. This strategy would require the CML cells to respond to stromal adhesion in the same way as normal cells (ie by reducing their proliferative fraction). Some studies indicate that this goal might be achieved, 45 but our data ( Figure 3) suggest that CML progenitor cells may not be sensitive to stromal cell-mediated negative regulation.
